BioMelbourne Network
Progressing BioIndustry

News and Opinions

Previous1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9

2014

July

IDT Executes Binding Memorandum of Understanding with Mayne Pharma for Exclusive Distribution of Temozolomide in the US

29th July, 2014 - IDT has now secured US distribution for its generic Temozolomide product on favourable commercial terms. IDT  Australia  Limited  (ASX:IDT)  is  pleased  to  announce  that  it  has entered  into  a  binding  Memorandum  of  Understanding  (MOU)  with  Mayne  Pharma’s  US Products  division  to  distribute  IDT’s  generic  Temozolomide  product  in  the  United  States  of Am... read more…

Collaboration announced to advance malaria vaccine development

29th July, 2014 - Burnet Institute and ARTES Biotechnology have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI).The project will use exciting novel technology developed at Burnet Institute by Deputy Director, Associate Professor David Anderson and colleagues. ARTES holds the international patent rights and adapted the platf... read more…

Phosphagenics Opioid Patch Program Update

28th July, 2014 - • Next phase of the TPM®/Oxymorphone clinical development program has commenced• TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4/2014• TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in H1/2015 Australian drug delivery company, Phosphagenics Limited (“the Company”) (ASX: POH, OTCQX: PPGNY), provides the following update on its opioid t... read more…

Business Council of Australi (BCA) - Actions Needed to Build Australia’s Comparative Advantages

28th July, 2014 - Continuing Australia’s remarkable run of economic growth will require businesses and governments to take more deliberate and purposeful steps in response to global forces of change, Business Council of Australia President Catherine Livingstone said today. Ms Livingstone used her first major speech as BCA President to launch a landmark paper that recommends a radical rethink o... read more…

Dr who? Campaign to boost digital profile of Australia's female scientists

27th July, 2014 - Ever heard of Dora Lush? She was an Australian microbiologist working in the 1940s on developing a vaccine for a deadly disease known as scrub typhus. She accidentally pricked her finger with a contaminated needle. Three weeks later, she died from the very disease she was trying to tame. Hailed as a martyr for science by her contemporaries, she kept donating blood samples fro... read more…

Acrux Appoints New CEO

25th July, 2014 - Acrux (ASX: ACR) today announced the appointment of a new Chief Executive Officer and Managing Director, Mr. Michael Kotsanis. Michael is currently Chief Commercial Officer of Synthon Holding BV in the Netherlands. He has 25 years’ experience in the global pharmaceutical industry, beginning his career with Boehringer Ingelheim before moving to F. H. Faulding (which was acquire... read more…

ADMEDUS INCREASES STAKE IN IAN FRAZER’S VACCINES

24th July, 2014 -  Now owns over 66% of Admedus Vaccines  Positive interim Phase I HSV-2 data     Phase II HSV-2 programme scheduled to be initiated by end of this year Admedus (ASX: AHZ) today announced that it has increased its ownership in Admedus Vaccines, the platform vaccine development company led by Professor Ian Frazer. Over the last twelve months Admedus has increased its ho... read more…

Starpharma and Ansell Get approval for HIV-killing Condom

23rd July, 2014 - An Australian-developed virus-killing condom is a step closer to sale, following a key regulatory approval. Australian biotech firm Starpharma has developed an antiviral compound called VivaGel that laboratory tests have shown can inactivate up to 99.9 per cent of HIV, herpes and some other sexually transmitted viruses, reducing the risk of transmission. It has teamed up wit... read more…

dorsaVi to commence sale of ViMove in the US following FDA clearance

23rd July, 2014 - Wearable medical device company dorsaVi Limited (ASX: DVL) has today announced it will commence launch of ViMove in the United States following 510K clearance by the US Food and Drug Administration (FDA) for measuring, recording, and reporting on movement and muscle activity of the lower back / lumbar spine. “This is a terrific achievement for dorsaVi and opens up substantial... read more…

Phosphagenics' $19.3 million Capital Raising

11th July, 2014 - • Includes $3 million Share Purchase Plan• Upcoming opioid pain patch trials fully funded 11 July 2014, Melbourne:  Australian drug delivery company, Phosphagenics Limited (ASX:POH; OTCQX:PPGNY),has raised $19.3 million via a placement of $16.3 million to institutional and sophisticated investors in Europe, USA, Asia and Australia and $3 million from a share purchase plan (SP... read more…